I've ruled out a "capital raise",imo, as they had over 300 million USD at June 30/22.
Institutional adjustments is a possibility, and it appeared that the sell off today was a continuation of the selloff that started last Friday afternoon.
Overall, these moves are all to common in biotech, impossible to predict, imo, and in this instance holding long term is the best strategy, imo, given the level of conviction i have in this company.